SCHEMBL102247

SCHEMBL102247

CN1CCC23c4c5ccc(O)c4O[C@H]2C(=O)C=C[C@@]3(O)C1C5

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 9/20 0.64
OPRD1 P41143 8/20 0.64
OPRK1 P41145 8/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3114799 1.00 OPRM1 (0.64) OPRM1OPRD1OPRK1
SCHEMBL17168337 1.00 OPRM1 (0.64) OPRM1OPRD1OPRK1
SCHEMBL16437865 1.00 OPRM1 (0.64) OPRM1OPRD1OPRK1
SCHEMBL10050599 1.00 OPRM1 (0.64) OPRM1OPRD1OPRK1
SCHEMBL138329 1.00 OPRM1 (0.64) OPRM1OPRD1OPRK1
SCHEMBL10301493 1.00 OPRM1 (0.64) OPRM1OPRD1OPRK1
SCHEMBL14883433 1.00 OPRM1 (0.64) OPRM1OPRD1OPRK1
SCHEMBL16926031 1.00 OPRM1 (0.64) OPRM1OPRD1OPRK1
SCHEMBL8285384 1.00 OPRM1 (0.64) OPRM1OPRD1OPRK1
SCHEMBL20683157 1.00 OPRM1 (0.64) OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200338068-A1 PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF a,ß-UNSATURATED KETONE COMPOUNDS SpecGx LLC (US) 2020-10-29 US disclosed
US-20190225622-A1 Process for the Preparation of Oxymorphone Alkaloid and Oxymorphone Salts JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2019-07-25 US disclosed
US-20180008596-A1 Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds MALLINCKRODT LLC (US) 2018-01-11 US disclosed
US-20150329553-A1 Process for the preparation of oxymorphone alkaloid and oxymorphone salts JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2015-11-19 US disclosed
US-9120800-B2 Process for the preparation of oxymorphone alkaloid and oxymorphone salts JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2015-09-01 US disclosed
US-20150148365-A1 Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds LIEBEL-FLARSHEIM COMPANY LLC 2015-05-28 US disclosed
WO-2015015146-A1 PROCESS FOR THE PREPARATION OF OXYMORPHONE JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2015-02-05 WO disclosed
US-20150038715-A1 PROCESS JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2015-02-05 US disclosed
US-8871779-B2 Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds MALLINCKRODT LLC (US) 2014-10-28 US disclosed
US-8871779-B2 Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds MALLINCKRODT LLC (US) 2014-10-28 US disclosed
US-8748611-B2 Processes for preparing morphinan-6-one products with low levels of alpha beta-unsaturated compounds MALLINCKRODT LLC (US) 2014-06-10 US disclosed
US-8748611-B2 Processes for preparing morphinan-6-one products with low levels of alpha beta-unsaturated compounds MALLINCKRODT LLC (US) 2014-06-10 US disclosed
US-20120059167-A1 PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF ALPHA BETA-UNSATURATED COMPOUNDS MALLINCKRODT INC. (US) 2012-03-08 US disclosed
US-20120059167-A1 PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF ALPHA BETA-UNSATURATED COMPOUNDS MALLINCKRODT INC. (US) 2012-03-08 US disclosed
US-20080312442-A1 Process for Preparing Morphinan-6-One Products with Low Levels of Alpha, Beta-Unsaturated Ketone Compounds SpecGx LLC 2008-12-18 US disclosed
US-20080312442-A1 Process for Preparing Morphinan-6-One Products with Low Levels of Alpha, Beta-Unsaturated Ketone Compounds SpecGx LLC 2008-12-18 US disclosed
WO-2007103105-A2 PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF ALPHA, BETA-UNSATURATED KETONE COMPOUNDS MALLINCKRODT INC. (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225622-A1 Process for the Preparation of Oxymorphone Alkaloid and Oxymorphone Salts OPRK1, OPRM1, OPRD1 OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885
US-20080312442-A1 Process for Preparing Morphinan-6-One Products with Low Levels of Alpha, Beta-Unsaturated Ketone Compounds FASN, CYP1B1, SULT1A1 OPRM1 73/4885OPRD1 46/4885OPRK1 105/4885
US-20150329553-A1 Process for the preparation of oxymorphone alkaloid and oxymorphone salts OPRK1, OPRM1, OPRD1 OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885
US-20200338068-A1 PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF a,ß-UNSATURATED KETONE COMPOUNDS FASN, CYP1B1, CLN6 OPRM1 76/4885OPRD1 62/4885OPRK1 123/4885
US-20150148365-A1 Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds FASN, CYP1B1, CLN6 OPRM1 69/4885OPRD1 50/4885OPRK1 98/4885
US-20120059167-A1 PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF ALPHA BETA-UNSATURATED COMPOUNDS FASN, DEGS1, CYP1B1 OPRM1 87/4885OPRD1 61/4885OPRK1 163/4885
US-20150038715-A1 PROCESS OPRK1, OPRD1, HMOX1 OPRM1 4/4885OPRD1 2/4885OPRK1 1/4885
US-20180008596-A1 Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds FASN, CYP1B1, CLN6 OPRM1 69/4885OPRD1 50/4885OPRK1 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.